Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Liabilities and Shareholders Equity of $1.3 billion for Q1 2026, down 7.41% year-over-year from $1.4 billion in Q1 2025, and little changed quarter-over-quarter from $1.3 billion in Q4 2025.
Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 7.41% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.5 billion (down 4.99% YoY), while the FY2025 annual figure was $1.3 billion, down 5.12% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.3 billion, roughly flat from $1.3 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.2 billion in Q4 2022, with the low at $1.3 billion in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2024), against an average of $2.0 billion.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity gained 7.05% in 2022, then sank 42.42% in 2023.
- Emergent BioSolutions' Liabilities and Shareholders Equity stood at $3.2 billion in 2022, then tumbled by 42.42% to $1.8 billion in 2023, then declined by 23.78% to $1.4 billion in 2024, then dropped by 5.12% to $1.3 billion in 2025, then gained by 0.14% to $1.3 billion in 2026.
- Business Quant data shows EBS's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | 1.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Bn |
| Mar 31, 2026 | 1.32 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | 1.43 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.51 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 1.89 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 2.95 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 2.90 Bn |
| Jun 30, 2022 | 2.74 Bn |
| Mar 31, 2022 | 2.78 Bn |
| Dec 31, 2021 | 2.96 Bn |
| Sep 30, 2021 | 2.87 Bn |